Base de dados : MEDLINE
Pesquisa : D01.200.275.150.100.800 [Categoria DeCS]
Referências encontradas : 4100 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 410 ir para página                         

  1 / 4100 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420536
[Au] Autor:Kooiman J; de Vries JPM; Van der Heyden J; Sijpkens YWJ; van Dijkman PRM; Wever JJ; van Overhagen H; Vahl AC; Aarts N; Verberk-Jonkers IJAM; Brulez HFH; Hamming JF; van der Molen AJ; Cannegieter SC; Putter H; van den Hout WB; Kilicsoy I; Rabelink TJ; Huisman MV
[Ad] Endereço:Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
[Ti] Título:Randomized trial of one-hour sodium bicarbonate vs standard periprocedural saline hydration in chronic kidney disease patients undergoing cardiovascular contrast procedures.
[So] Source:PLoS One;13(2):e0189372, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Guidelines advise periprocedural saline hydration for prevention of contrast induced-acute kidney injury (CI-AKI). We analysed whether 1-hour sodium bicarbonate hydration administered solely prior to intra-arterial contrast exposure is non-inferior to standard periprocedural saline hydration in chronic kidney disease (CKD) patients undergoing elective cardiovascular diagnostic or interventional contrast procedures. METHODS: We performed an open-label multicentre non-inferiority trial between 2011-2014. Patients were randomized to 1 hour pre-procedure sodium bicarbonate hydration (250 ml 1.4%, N = 168) or 4-12 hours saline hydration (1000 ml 0.9%, N = 165) prior to and following contrast administration (2000 ml of saline total). Primary outcome was the relative serum creatinine increase (%) 48-96 hours post contrast exposure. Secondary outcomes were: incidence of CI-AKI (serum creatinine increase>25% or >44µmol/L), recovery of renal function, the need for dialysis, and hospital costs within two months follow-up. RESULTS: Mean relative creatinine increase was 3.1% (95%CI 0.9 to 5.2%) in the bicarbonate and 1.1% (95%CI -1.2 to 3.5%) in the saline arm, mean difference 1.9% (95%CI -1.2 to 5.1%, p-non-inferiority <0.001). CI-AKI occurred in 11 (6.7%) patients randomized to sodium bicarbonate and 12 (7.5%) to saline (p = 0.79). Renal function did not fully recover in 40.0% and 44.4% of CI-AKI patients, respectively (p = 0.84). No patient required dialysis. Mean costs for preventive hydration and clinical preparation for the contrast procedure were $1158 for sodium bicarbonate vs. $1561 for saline (p < 0.001). CONCLUSION: Short hydration with sodium bicarbonate prior to elective cardiovascular diagnostic or therapeutic contrast procedures is non-inferior to standard periprocedural saline hydration in CKD patients with respect to renal safety and results in considerable healthcare savings. TRIAL REGISTRATION: Netherlands Trial Register (http://www.trialregister.nl/trialreg/index.asp), Nr NTR2699.
[Mh] Termos MeSH primário: Lesão Renal Aguda/prevenção & controle
Sistema Cardiovascular/diagnóstico por imagem
Meios de Contraste/efeitos adversos
Falência Renal Crônica/terapia
Bicarbonato de Sódio/administração & dosagem
Cloreto de Sódio/administração & dosagem
[Mh] Termos MeSH secundário: Lesão Renal Aguda/induzido quimicamente
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contrast Media); 451W47IQ8X (Sodium Chloride); 8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189372


  2 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240374
[Au] Autor:Goldfarb DS; Grasso M
[Ti] Título:Case Study - Case Studies in Cystinuria.
[So] Source:Urol Nurs;37(2):90-3, 2017 Mar-Apr.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The diagnosis and treatment of patients with rare inherited metabolic disorders associated with recurrent and often obstructive kidney stones are important to the prevention of chronic kidney disease or end stage renal disease. Two case studies in this article describe the diagnosis and management of cystinuria, the most common rare kidney stone disorder.
[Mh] Termos MeSH primário: Cistinúria/diagnóstico
Íleo/transplante
Cálculos Renais/cirurgia
Ureter/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Cistinúria/complicações
Cistinúria/terapia
Dietoterapia
Diuréticos/uso terapêutico
Feminino
Hidratação
Seres Humanos
Cálculos Renais/etiologia
Masculino
Adesão à Medicação
Citrato de Potássio/uso terapêutico
Procedimentos Cirúrgicos Reconstrutivos
Insuficiência Renal Crônica/etiologia
Bicarbonato de Sódio
Tiopronina/uso terapêutico
Tomografia Computadorizada por Raios X
Ureteroscopia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Diuretics); 8MDF5V39QO (Sodium Bicarbonate); C5W04GO61S (Tiopronin); EE90ONI6FF (Potassium Citrate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  3 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28836872
[Au] Autor:Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
[Ad] Endereço:a Research Department , Technostics Limited, Castle Hill Hospital , Cottingham , UK.
[Ti] Título:A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
[So] Source:Drug Dev Ind Pharm;44(1):30-39, 2018 Jan.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Research to measure the chemical characterization of alginate rafts for good raft performance and ascertain how formulation can affect chemical parameters. SIGNIFICANCE: A selection of alginate formulations was investigated all claiming to be proficient raft formers with significance between products established and ranked. METHODS: Procedures were selected which demonstrated the chemical characterization allowing rafts to effectively impede the reflux into the esophagus or in severe cases to be refluxed preferentially into the esophagus and exert a demulcent effect, with focus of current research on methods which complement previous studies centered on physical properties. The alginate content was analyzed by a newly developed HPLC method. Methods were used to determine the neutralization profile and the acid neutralization within the raft determined along with how raft structure affects neutralization. RESULTS: Alginate content of Gaviscon Double Action (GDA) within the raft was significantly superior (p < .0001) to all competitor products. The two products with the highest raft acid neutralization capacity were GDA and Rennie Duo, the latter product not being a raft former. Raft structure was key and GDA had the right level of porosity to allow for longer duration of neutralization. CONCLUSION: Alginate formulations require three chemical reactions to take place simultaneously: transformation to alginic acid, sodium carbonate reacting to form carbon dioxide, calcium releasing free calcium ions to bind with alginic acid providing strength to raft formation. GDA was significantly superior (p <.0001) to all other comparators.
[Mh] Termos MeSH primário: Alginatos/química
Hidróxido de Alumínio/química
Antiácidos/química
Carbonato de Cálcio/química
Carbonatos/química
Esôfago/química
Refluxo Gastroesofágico/tratamento farmacológico
Magnésio/química
Ácido Silícico/química
Bicarbonato de Sódio/química
[Mh] Termos MeSH secundário: Alginatos/farmacologia
Alginatos/uso terapêutico
Antiácidos/metabolismo
Antiácidos/uso terapêutico
Combinação de Medicamentos
Impedância Elétrica
Refluxo Gastroesofágico/metabolismo
Ácido Glucurônico/química
Ácido Glucurônico/farmacologia
Ácido Glucurônico/uso terapêutico
Ácidos Hexurônicos/química
Ácidos Hexurônicos/farmacologia
Ácidos Hexurônicos/uso terapêutico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Antacids); 0 (Carbonates); 0 (Drug Combinations); 0 (Hexuronic Acids); 1343-98-2 (Silicic Acid); 45P3261C7T (sodium carbonate); 5QB0T2IUN0 (Aluminum Hydroxide); 66220-44-8 (alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination); 82351-35-7 (Rennie); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid); 8MDF5V39QO (Sodium Bicarbonate); H0G9379FGK (Calcium Carbonate); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1371737


  4 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464343
[Au] Autor:Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
[Ad] Endereço:RB, Slough, Berkshire, UK.
[Ti] Título:Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
[So] Source:Aliment Pharmacol Ther;45(12):1524-1533, 2017 06.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Symptomatic breakthrough in proton pump inhibitor (PPI)-treated gastro-oesophageal reflux disease (GERD) patients is a common problem with a range of underlying causes. The nonsystemic, raft-forming action of alginates may help resolve symptoms. AIM: To assess alginate-antacid (Gaviscon Double Action, RB, Slough, UK) as add-on therapy to once-daily PPI for suppression of breakthrough reflux symptoms. METHODS: In two randomised, double-blind studies (exploratory, n=52; confirmatory, n=262), patients taking standard-dose PPI who had breakthrough symptoms, assessed by Heartburn Reflux Dyspepsia Questionnaire (HRDQ), were randomised to add-on Gaviscon or placebo (20 mL after meals and bedtime). The exploratory study endpoint was change in HRDQ score during treatment vs run-in. The confirmatory study endpoint was "response" defined as ≥3 days reduction in the number of "bad" days (HRDQ [heartburn/regurgitation] >0.70) during treatment vs run-in. RESULTS: In the exploratory study, significantly greater reductions in HRDQ scores (heartburn/regurgitation) were observed in the Gaviscon vs placebo (least squares mean difference [95% CI] -2.10 [-3.71 to -0.48]; P=.012). Post hoc "responder" analysis of the exploratory study also revealed significantly more Gaviscon patients (75%) achieved ≥3 days reduction in "bad" days vs placebo patients (36%), P=.005. In the confirmatory study, symptomatic improvement was observed with add-on Gaviscon (51%) but there was no significant difference in response vs placebo (48%) (OR (95% CI) 1.15 (0.69-1.91), P=.5939). CONCLUSIONS: Adding Gaviscon to PPI reduced breakthrough GERD symptoms but a nearly equal response was observed for placebo. Response to intervention may vary according to whether symptoms are functional in origin.
[Mh] Termos MeSH primário: Alginatos/administração & dosagem
Hidróxido de Alumínio/administração & dosagem
Antiácidos/administração & dosagem
Dor Irruptiva/tratamento farmacológico
Refluxo Gastroesofágico/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
Ácido Silícico/administração & dosagem
Bicarbonato de Sódio/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Alginatos/efeitos adversos
Hidróxido de Alumínio/efeitos adversos
Antiácidos/efeitos adversos
Antiulcerosos/administração & dosagem
Antiulcerosos/efeitos adversos
Método Duplo-Cego
Combinação de Medicamentos
Feminino
Azia/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/efeitos adversos
Ácido Silícico/efeitos adversos
Bicarbonato de Sódio/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Alginates); 0 (Antacids); 0 (Anti-Ulcer Agents); 0 (Drug Combinations); 0 (Proton Pump Inhibitors); 1343-98-2 (Silicic Acid); 5QB0T2IUN0 (Aluminum Hydroxide); 66220-44-8 (alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination); 8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14064


  5 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29020034
[Au] Autor:Guan Q; Liao X; He M; Li X; Wang Z; Ma H; Yu S; Liu S
[Ad] Endereço:Key Laboratory of Saline-alkali Vegetation Ecology Restoration (SAVER), Ministry of Education, Alkali Soil Natural Environmental Science Center (ASNESC), Northeast Forestry University, Harbin, China.
[Ti] Título:Tolerance analysis of chloroplast OsCu/Zn-SOD overexpressing rice under NaCl and NaHCO3 stress.
[So] Source:PLoS One;12(10):e0186052, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The 636-bp-long cDNA sequence of OsCu/Zn-SOD (AK059841) was cloned from Oryza sativa var. Longjing11 via reverse transcription polymerase chain reaction (RT-PCR). The encoded protein comprised of 211 amino acids is highly homologous to Cu/Zn-SOD proteins from tuscacera rice and millet. Quantitative RT-PCR revealed that in rice, the level of OsCu/Zn-SOD gene expression was lowest in roots and was highest in petals and during the S5 leaf stage. Moreover, the expression level of OsCu/Zn-SOD gene expression decreased during the L5 leaf stage to maturity. The level of OsCu/Zn-SOD gene expression, however, was increased under saline-sodic stress and NaHCO3 stress. Germination tests under 125, 150, and 175 mM NaCl revealed that OsCu/Zn-SOD-overexpressing lines performed better than the non-transgenic (NT) Longjing11 lines in terms of germination rate and height. Subjecting seedlings to NaHCO3 and water stress revealed that OsCu/Zn-SOD-overexpressing lines performed better than NT in terms of SOD activity, fresh weight, root length, and height. Under simulated NaHCO3 stress, OsCu/Zn-SOD-overexpressing lines performed better than NT in terms of survival rate (25.19% > 6.67%) and yield traits (average grain weight 20.6 > 18.15 g). This study showed that OsCu/Zn-SOD gene overexpression increases the detoxification capacity of reactive oxygen species in O. sativa and reduces salt-induced oxidative damage. We also revealed the regulatory mechanism of OsCu/Zn-SOD enzyme in saline-sodic stress resistance in O. sativa. Moreover, we provided an experimental foundation for studying the mechanism of OsCu/Zn-SOD enzymes in the chloroplast.
[Mh] Termos MeSH primário: Adaptação Fisiológica/efeitos dos fármacos
Cloroplastos/enzimologia
Oryza/enzimologia
Oryza/fisiologia
Bicarbonato de Sódio/farmacologia
Cloreto de Sódio/farmacologia
Estresse Fisiológico/efeitos dos fármacos
Superóxido Dismutase-1/metabolismo
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Clonagem Molecular
Regulação da Expressão Gênica de Plantas/efeitos dos fármacos
Vetores Genéticos/metabolismo
Proteínas de Fluorescência Verde/metabolismo
Oryza/efeitos dos fármacos
Oryza/genética
Filogenia
Plantas Geneticamente Modificadas
Espécies Reativas de Oxigênio/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
Plântulas/efeitos dos fármacos
Plântulas/crescimento & desenvolvimento
Alinhamento de Sequência
Frações Subcelulares/efeitos dos fármacos
Frações Subcelulares/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Reactive Oxygen Species); 147336-22-9 (Green Fluorescent Proteins); 451W47IQ8X (Sodium Chloride); 8MDF5V39QO (Sodium Bicarbonate); EC 1.15.1.1 (Superoxide Dismutase-1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186052


  6 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28844518
[Au] Autor:Alonso P; Sanz J; García-Orts A; Reina S; Jiménez S; Osca J; Cano O; Andrés A; Sancho-Tello MJ; Martínez L
[Ad] Endereço:Electrophysiology Section, Cardiology Department, La Fe University Hospital, Valencia, Spain. Electronic address: pau.alonso.fernandez@gmail.com.
[Ti] Título:Usefulness of Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Resynchronization Therapy.
[So] Source:Am J Cardiol;120(9):1584-1588, 2017 Nov 01.
[Is] ISSN:1879-1913
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of contrast media during cardiac resynchronization therapy (CRT) devices implantation is associated with the risk of contrast-induced nephropathy (CIN). The aim of this study was to evaluate the possible beneficial role of periprocedural intravenous volume expansion with isotonic saline and sodium bicarbonate solution in patients who undergo CRT implantation. Eligible patients were randomly assigned in a 1:1 ratio to receive hydration plus one-sixth molar sodium bicarbonate (study group) or not (control group). Primary end point was CIN incidence. Secondary end points were (1) a combined end point of death, heart transplantation, or hospitalization for heart failure at 12 months, (2) incidence of death, and (3) the need for renal replacement therapy at 12 months. Final analysis was performed with 93 patients. In the hydration group CIN incidence was significantly reduced related to control group (0% vs 11%, p = 0.02). There was a trend to reduce the combined end point in hydration group (12.5% vs 22%, p = 0.14). Finally, CIN incidence was related to a higher 12 months mortality (25% vs 7%, p = 0.03). In conclusion, CIN incidence was 11% in a nonselected population of patients receiving a CRT device. CIN appearance could be reduced by using a hydration protocol based on sodium bicarbonate and isotonic saline.
[Mh] Termos MeSH primário: Arritmias Cardíacas/terapia
Terapia de Ressincronização Cardíaca
Meios de Contraste/efeitos adversos
Nefropatias/induzido quimicamente
Nefropatias/prevenção & controle
Bicarbonato de Sódio/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Arritmias Cardíacas/complicações
Arritmias Cardíacas/mortalidade
Feminino
Hospitalização
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Contrast Media); 8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  7 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28797049
[Au] Autor:Freis T; Hecksteden A; Such U; Meyer T
[Ad] Endereço:Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany.
[Ti] Título:Effect of sodium bicarbonate on prolonged running performance: A randomized, double-blind, cross-over study.
[So] Source:PLoS One;12(8):e0182158, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The ability to sustain intense exercise seems to be partially limited by the body's capability to counteract decreases in both intra- and extracellular pH. While the influence of an enhanced buffering capacity via sodium bicarbonate (BICA) on short-term, high-intensity exercise performance has been repeatedly investigated, studies on prolonged endurance performances are comparatively rare, especially for running. The aim of the following study was to assess the ergogenic effects of an oral BICA substitution upon exhaustive intensive endurance running performance. METHOD: In a double-blind randomized cross-over study, 18 trained runners (VO2peak: 61.2 ± 6.4 ml•min-1•kg-1) performed two exhaustive graded exercise tests and two constant load tests (30 main at 95% individual anaerobic threshold (IAT) followed by 110% IAT until exhaustion) after ingestion of either sodium bicarbonate (BICA) (0.3 g/kg) or placebo (4 g NaCl) diluted in 700 ml of water. Time to exhaustion (TTE) in the constant load test was defined as the main outcome measure. Throughout each test respiratory gas exchange measurements were conducted as well as determinations of heart rate, blood gases and blood lactate concentration. RESULTS: TTE in the constant load test did not differ significantly between BICA and placebo conditions (BICA: 39.6 ± 5.6 min, placebo: 39.3 ± 5.6 min; p = 0.78). While pH in the placebo test dropped to a slightly acidotic value two minutes after cessation of exercise (7.34 ± 0.05) the value in the BICA trial remained within the normal range (7.41 ± 0.06) (p < 0.001). In contrast, maximum running speed (Vmax) in the exhaustive graded exercise test was significantly higher with BICA (17.4 ± 1.0 km/h) compared to placebo (17.1 ± 1.0 km/h) (p = 0.009). The numerical difference in maximum oxygen consumption (VO2peak) failed to reach statistical significance (BICA: 61.2 ± 6.4 ml•min-1•kg-1, placebo: 59.8 ± 6.4 ml•min-1•kg-1; p = 0.31). Maximum blood lactate was significantly higher with BICA compared to the corresponding placebo test (BICA: 11.1 ± 2.3 mmol/l, placebo: 8.9 ± 3.0 mmol/l; p < 0.001). At the end of exercise, an acidotic pH value was found in both exhaustive graded exercise tests (p = 0.002). BICA caused gastrointestinal side effects in 15 patients. CONCLUSION: Maximal performance was enhanced significantly after BICA administration. The ergogenic effect of BICA in the exhaustive graded exercise test can most likely be attributed to an increased anaerobic glycolysis that is reflected by an accumulation of lactate. However, TTE in prolonged high-intensity running was not improved. Even at the end of exercise no severe metabolic acidosis was found. Metabolic acidification as one of the dominant factors causing muscular fatigue should therefore be reconsidered. TRIAL REGISTRATION: German Clinical Trials Register (DRKS) DRKS00011284.
[Mh] Termos MeSH primário: Limiar Anaeróbio/efeitos dos fármacos
Fadiga Muscular/efeitos dos fármacos
Consumo de Oxigênio/efeitos dos fármacos
Resistência Física/efeitos dos fármacos
Corrida/fisiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Limiar Anaeróbio/fisiologia
Estudos Cross-Over
Método Duplo-Cego
Teste de Esforço
Feminino
Seres Humanos
Masculino
Fadiga Muscular/fisiologia
Consumo de Oxigênio/fisiologia
Resistência Física/fisiologia
Bicarbonato de Sódio/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182158


  8 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28697113
[Au] Autor:Soon R; Tschann M; Salcedo J; Stevens K; Ahn HJ; Kaneshiro B
[Ad] Endereço:Department of Obstetrics, Gynecology & Women's Health and the Office of Biostatistics & Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii.
[Ti] Título:Paracervical Block for Laminaria Insertion Before Second-Trimester Abortion: A Randomized Controlled Trial.
[So] Source:Obstet Gynecol;130(2):387-392, 2017 Aug.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy of a paracervical block to decrease pain during osmotic dilator insertion before second-trimester abortion. METHODS: In this double-blind, randomized trial, 41 women undergoing Laminaria insertion before a second-trimester abortion received either a paracervical block with 18 mL 1% lidocaine and 2 mL sodium bicarbonate or a sham block. Women were between 14 and 23 6/7 weeks of gestation. The primary outcome was pain immediately after insertion of Laminaria. Women assessed their pain on a 100-mm visual analog scale. Secondary outcomes included assessment of pain at other times during the insertion procedure and overall satisfaction with pain control. To detect a 25-mm difference in pain immediately after Laminaria insertion, at an α of 0.05 and 80% power, we aimed to enroll 20 patients in each arm. RESULTS: From May 2015 to December 2015, 20 women received a paracervical block and 21 received a sham block. Groups were similar in demographics, including parity, history of surgical abortion, and number of Laminaria placed. The paracervical block reduced pain after Laminaria insertion (median scores 13 mm [interquartile range 2-39] compared with 54 mm [interquartile range 27-61], P=.01, 95% CI -47.0 to -4.0). Women who received a paracervical block also reported higher satisfaction with overall pain control throughout the entire Laminaria insertion procedure (median scores 95 mm [interquartile range 78-100] compared with 70 mm [interquartile range 44-90], P=.05, 95% CI 0.0-37.0). CONCLUSION: Paracervical block is effective at reducing the pain of Laminaria insertion. Additionally, a paracervical block increases overall patient satisfaction with pain control during Laminaria placement. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02454296.
[Mh] Termos MeSH primário: Anestesia Obstétrica/métodos
Idade Gestacional
Laminaria
[Mh] Termos MeSH secundário: Aborto Induzido/métodos
Adulto
Método Duplo-Cego
Feminino
Hawaii
Seres Humanos
Lidocaína/administração & dosagem
Medição da Dor
Satisfação do Paciente
Gravidez
Segundo Trimestre da Gravidez
Bicarbonato de Sódio/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
8MDF5V39QO (Sodium Bicarbonate); 98PI200987 (Lidocaine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002149


  9 / 4100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28672414
[Au] Autor:Geiger H; Jung O
[Ti] Título:[Therapy of Intradialytic Chronic Metabolic Acidosis in Germany - Is it According to Latest Evidence?]
[Ti] Título:Therapie der chronischen metabolischen Azidose bei Hämodialysepatienten in Deutschland ­ Sind wir auf dem neuesten Stand?.
[So] Source:Dtsch Med Wochenschr;142(13):e89-e94, 2017 Jul.
[Is] ISSN:1439-4413
[Cp] País de publicação:Germany
[La] Idioma:ger
[Ab] Resumo:Chronic metabolic acidosis is a frequent comorbidity in chronic kidney disease, especially in patients undergoing dialysis. Recent study data suggest that treatment of acidosis during dialysis with bicarbonate may result in increased levels of serum bicarbonate, which is associated with increased mortality. We aimed to evaluate the current management of chronic metabolic acidosis in Germany: have recent study results been transferred into daily routine and are nephrologists aware of these new study data? Therefore, we did a survey with 17 questions among 2096 German nephrologists. 280 valid responses were returned and analysed with descriptive statistics. Blood gas analysis was done weekly (27 % of respondents), monthly (20 %), every 3 months (19 %), less frequently (5 %) or not routinely (3 %). It was done by most respondents prior to the dialysis session (83 %) and by some (20 %) also afterwards or during the session (3 %). 20 % did blood gas analysis "as required".Oral bicarbonate was discontinued at start of dialysis by 66 % of nephrologists; 22 % of these do generally not use it and 44 % usually discontinue it but might continue if required. 34 % of responding nephrologists continue oral bicarbonate when starting dialysis but might adjust dose. Recent study data might have to be better promoted among nephrologists. Although KDIGO guidelines recommend at least monthly blood gas analysis, about one quarter of nephrologists stated to do it less frequently. Furthermore, blood gas analysis was rarely done after dialysis treatment and thus, important information about success or failure of bicarbonate correction was not obtained. If alkalotic episodes after dialysis treatment would be detected this way, regular oral bicarbonate might be an option for correction of metabolic acidosis.
[Mh] Termos MeSH primário: Acidose/mortalidade
Acidose/prevenção & controle
Fidelidade a Diretrizes/utilização
Padrões de Prática Médica/normas
Padrões de Prática Médica/utilização
Diálise Renal/normas
[Mh] Termos MeSH secundário: Doença Crônica
Medicina Baseada em Evidências
Alemanha/epidemiologia
Fidelidade a Diretrizes/normas
Seres Humanos
Guias de Prática Clínica como Assunto
Prevalência
Diálise Renal/mortalidade
Fatores de Risco
Bicarbonato de Sódio/administração & dosagem
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1055/s-0042-123528


  10 / 4100 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581835
[Au] Autor:Sharma BG; Khanna K; Kumar N; Nishad DK; Basu M; Bhatnagar A
[Ad] Endereço:a Research and Development Division , Hetero Healthcare Pvt Ltd , Hyderabad , India.
[Ti] Título:Development and gamma scintigraphy evaluation of gastro retentive calcium ion-based oral formulation: an innovative approach for the management of gastro-esophageal reflux disease (GERD).
[So] Source:Drug Dev Ind Pharm;43(11):1759-1769, 2017 Nov.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Calcium chloride is an essential calcium channel agonist which plays an important role in the contraction of muscles by triggering calcium channel. First time hypothesized about its role in the treatment of GER (gastro-esophageal reflux) and vomiting disorder due to its local action. There are two objectives covered in this study as first, the development and optimization of floating formulation of calcium chloride and another objective was to evaluate optimized formulation through gamma scintigraphy in human subjects. Gastro retentive formulation of calcium chloride was prepared by direct compression method. Thirteen tablet formulations were designed with the help of sodium chloride, HPMC-K4M, and carbopol-934 along with effervescing agent sodium bicarbonate and citric acid. Formulation (F8) fitted best for Korsmeyer-Peppas equation with an R value of 0.993. The optimized formulation was radiolabelled with Tc-99 m pertechnetate for its evaluation by gamma scintigraphy. Gastric retention (6 h) was evaluated by gamma scintigraphy in healthy human subjects and efficacy of present formulation confirmed in GER positive human subjects. Gamma scintigraphy results indicated its usefulness in order to manage GERD. Stability studies of the developed formulation were carried out as per ICH guidelines for region IV and found out to be stable for 24 months.
[Mh] Termos MeSH primário: Acrilatos/química
Canais de Cálcio/metabolismo
Refluxo Gastroesofágico/metabolismo
Cintilografia
Compostos Radiofarmacêuticos/química
Bicarbonato de Sódio/química
Comprimidos/administração & dosagem
Tecnécio/química
[Mh] Termos MeSH secundário: Administração Oral
Disponibilidade Biológica
Canais de Cálcio/química
Química Farmacêutica
Seres Humanos
Compostos Radiofarmacêuticos/metabolismo
Bicarbonato de Sódio/metabolismo
Comprimidos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylates); 0 (Calcium Channels); 0 (Radiopharmaceuticals); 0 (Tablets); 0 (carbopol 934P); 7440-26-8 (Technetium); 8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1339080



página 1 de 410 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde